Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 14/20 | 1.00 |
| ▸ | GABBR1 | Q9UBS5 | 14/20 | 1.00 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3123805 | 0.83 | GABBR2 (1.00) | GABBR2GABBR1 | |
| SCHEMBL3119366 | 0.83 | GABBR2 (1.00) | GABBR2GABBR1 | |
| SCHEMBL3119363 | 0.83 | GABBR2 (1.00) | GABBR2GABBR1 | |
| SCHEMBL3123795 | 0.83 | GABBR2 (1.00) | GABBR2GABBR1 | |
| SCHEMBL3119355 | 0.83 | GABBR2 (1.00) | GABBR2GABBR1 | |
| SCHEMBL3121907 | 0.80 | GABBR2 (1.00) | GABBR2GABBR1PDE10A | |
| SCHEMBL3111419 | 0.79 | GABBR2 (1.00) | GABBR2GABBR1PDE10A | |
| SCHEMBL3118358 | 0.79 | GABBR2 (1.00) | GABBR2GABBR1PDE10A | |
| SCHEMBL13268129 | 0.76 | GABBR2 (0.79) | GABBR2GABBR1PDE10A | |
| SCHEMBL26257034 | 0.75 | GABBR2 (0.63) | GABBR2GABBR1PDE10ACYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-15 | — | — | US | disclosed |
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-15 | — | — | US | disclosed |
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-15 | — | — | US | disclosed |
| EP-1896428-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OP GABA B MEDIATED NERVOUS SYSTEM DISORDERS | Novartis AG (CH) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006136442-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OP GABA B MEDIATED NERVOUS SYSTEM DISORDERS | NOVARTIS AG (CH) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | DPYD, NUDT1, HPRT1 | GABBR2 1611/4885GABBR1 1499/4885PDE10A 1353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.